Rates of Infections, Malignancies, Cardiovascular Outcomes, and Death in Individuals with Hospital-treated Alopecia Areata: A Registry-based Cohort Study in Denmark
DOI:
https://doi.org/10.2340/actadv.v105.42646Keywords:
alopecia areata, cardiovascular, cohort study, Denmark, infections, neoplasmsAbstract
The emergence of new systemic treatments for alopecia areata underscores the importance of estimating rates of potential treatment safety events among individuals with alopecia areata. In this population-based cohort study, data linked across Danish population-based registries were used to examine the rates of the following safety events of interest before approval of Janus kinase inhibitor treatments by the European Medicines Agency: serious infections, herpes zoster infections, malignancies, arterial and venous cardiovascular events, and all-cause death in an alopecia areata cohort, defined as individuals ≥ 12 years old with hospital-treated alopecia areata, including its sub-types alopecia totalis and alopecia universalis. Incidence rates of the safety events of interest were computed and their associations with alopecia areata were estimated as standardized incidence ratios computed with regard to the age- and sex-matched general Danish population. The alopecia areata cohort included 2,778 individuals (472 with alopecia totalis/alopecia universalis) with a first-recorded diagnosis of alopecia areata in 1995–2016, followed through to the end of 2016, during a hospital admission or treatment at an outpatient clinic. Hospital-treated alopecia areata was associated with serious infections (standardized incidence ratio [95% confidence interval], 1.89 [1.72–2.06]), herpes zoster infections (1.83 [1.63–2.05]), lymphoma (3.44 [1.88–5.77]), arterial and venous cardiovascular outcomes (1.41 [1.12–1.75]), and death (1.16 [1.00–1.34]).
Downloads
References
Lintzeri DA, Constantinou A, Hillmann K, Ghoreschi K, Vogt A, Blume-Peytavi U. Alopecia areata: current understanding and management. J Dtsch Dermatol Ges 2022; 20: 59–90.
https://doi.org/10.1111/ddg.14689 DOI: https://doi.org/10.1111/ddg.14689
Al Aboud AM, Syed HA, Zito PM. Alopecia. [Updated 2024 Feb 26] In: StatPearls [Internet] [cited 2024, 24 June]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK538178/.
Muntyanu A, Gabrielli S, Donovan J, Gooderham M, Guenther L, Hanna S, et al. The burden of alopecia areata: a scoping review focusing on quality of life, mental health and work productivity. J Eur Acad Dermatol Venereol 2023; 37: 1490–1520.
https://doi.org/10.1111/jdv.18926 DOI: https://doi.org/10.1111/jdv.18926
Ly S, Manjaly P, Kamal K, Shields A, Wafae B, Afzal N, et al. Comorbid conditions associated with alopecia areata: a systematic review and meta-analysis. Am J Clin Dermatol 2023; 24: 875–893.
https://doi.org/10.1007/s40257-023-00805-4 DOI: https://doi.org/10.1007/s40257-023-00805-4
(EMA) EMA. Olumiant (baricitinib) 2023 [cited 2023, 05 November]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/olumiant.
(EMA) EMA. Litfulo (ritlecitinib) 2023 [cited 2023, 05 November]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/litfulo.
King B, Mostaghimi A, Shimomura Y, Zlotogorski A, Choi GS, Blume-Peytavi U, et al. Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials. Br J Dermatol 2023; 188: 218–227.
https://doi.org/10.1093/bjd/ljac059 DOI: https://doi.org/10.1093/bjd/ljac059
King B, Soung J, Tziotzios C, Rudnicka L, Joly P, Gooderham M, et al. Integrated safety analysis of ritlecitinib, an oral JAK3/TEC family kinase inhibitor, for the treatment of alopecia areata from the ALLEGRO Clinical Trial Program. Am J Clin Dermatol 2024; 25: 299–314.
https://doi.org/10.1007/s40257-024-00846-3 DOI: https://doi.org/10.1007/s40257-024-00846-3
Papierzewska M, Waskiel-Burnat A, Rudnicka L. Safety of Janus kinase inhibitors in patients with alopecia areata: a systematic review. Clin Drug Investig 2023; 43: 325–334.
https://doi.org/10.1007/s40261-023-01260-z DOI: https://doi.org/10.1007/s40261-023-01260-z
Chen Y, Zhu H, Shen Y, Zhu Y, Sun J, Dai Y, et al. Efficacy and safety of JAK inhibitors in the treatment of alopecia areata in children: a systematic review and meta-analysis. J Dermatolog Treat 2022; 33: 3143–3149.
https://doi.org/10.1080/09546634.2022.2133956 DOI: https://doi.org/10.1080/09546634.2022.2133956
Chim I, Ghiya R, Sinclair RD, Eisman S. Novel investigational drugs for alopecia areata and future perspectives. Expert Opin Investig Drugs 2024; 33: 441–449.
https://doi.org/10.1080/13543784.2024.2348062 DOI: https://doi.org/10.1080/13543784.2024.2348062
Harigai M. Growing evidence of the safety of JAK inhibitors in patients with rheumatoid arthritis. Rheumatology (Oxford) 2019; 58: i34–i42.
https://doi.org/10.1093/rheumatology/key287 DOI: https://doi.org/10.1093/rheumatology/key287
Sunzini F, McInnes I, Siebert S. JAK inhibitors and infections risk: focus on herpes zoster. Ther Adv -Musculoskelet Dis 2020; 12: 1759720X20936059.
https://doi.org/10.1177/1759720X20936059 DOI: https://doi.org/10.1177/1759720X20936059
Winthrop KL. The emerging safety profile of JAK inhibitors in rheumatic disease. Nat Rev Rheumatol 2017; 13: 320.
https://doi.org/10.1038/nrrheum.2017.51 DOI: https://doi.org/10.1038/nrrheum.2017.51
Kang JH, Lin HC, Kao S, Tsai MC, Chung SD. Alopecia areata increases the risk of stroke: a 3-year follow-up study. Sci Rep 2015; 5: 11718.
https://doi.org/10.1038/srep11718 DOI: https://doi.org/10.1038/srep11718
Sorensen SBT, George P, Jagun O, Wolk R, Napatalung L, Zwillich SH, et al. The epidemiology of hospital-treated alopecia areata in Denmark, 1995–2016. Dermatol Ther (Heidelb) 2024; 14: 993–1006.
https://doi.org/10.1007/s13555-024-01145-9 DOI: https://doi.org/10.1007/s13555-024-01145-9
Schmidt M, Schmidt SAJ, Adelborg K, Sundboll J, Laugesen K, Ehrenstein V, et al. The Danish health care system and epidemiological research: from health care contacts to database records. Clin Epidemiol 2019; 11: 563–591.
https://doi.org/10.2147/CLEP.S179083 DOI: https://doi.org/10.2147/CLEP.S179083
Schmidt M, Pedersen L, Sorensen HT. The Danish Civil Registration System as a tool in epidemiology. Eur J Epidemiol 2014; 29: 541–549.
https://doi.org/10.1007/s10654-014-9930-3 DOI: https://doi.org/10.1007/s10654-014-9930-3
Schmidt M, Schmidt SA, Sandegaard JL, Ehrenstein V, Pedersen L, Sorensen HT. The Danish National Patient Registry: a review of content, data quality, and research potential. Clin Epidemiol 2015; 7: 449–490.
https://doi.org/10.2147/CLEP.S91125 DOI: https://doi.org/10.2147/CLEP.S91125
Gjerstorff ML. The Danish Cancer Registry. Scand J Public Health 2011; 39: 42–45.
https://doi.org/10.1177/1403494810393562 DOI: https://doi.org/10.1177/1403494810393562
Helweg-Larsen K. The Danish Register of Causes of Death. Scand J Public Health 2011; 39: 26–29.
https://doi.org/10.1177/1403494811399958 DOI: https://doi.org/10.1177/1403494811399958
Johannesdottir SA, Horvath-Puho E, Ehrenstein V, Schmidt M, Pedersen L, Sorensen HT. Existing data sources for clinical epidemiology: the Danish National Database of Reimbursed Prescriptions. Clin Epidemiol 2012; 4: 303–313.
https://doi.org/10.2147/CLEP.S37587 DOI: https://doi.org/10.2147/CLEP.S37587
King B, Zhang X, Harcha WG, Szepietowski JC, Shapiro J, Lynde C, et al. Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b-3 trial. Lancet 2023; 401: 1518–1529.
https://doi.org/10.1016/S0140-6736(23)00222-2 DOI: https://doi.org/10.1016/S0140-6736(23)00222-2
Holland-Bill L, Xu H, Sorensen HT, Acquavella J, Svaerke C, Gammelager H, et al. Positive predictive value of primary inpatient discharge diagnoses of infection among cancer patients in the Danish National Registry of Patients. Ann Epidemiol 2014; 24: 593–7, 97 e1–18.
https://doi.org/10.1016/j.annepidem.2014.05.011 DOI: https://doi.org/10.1016/j.annepidem.2014.05.011
Akyea RK, Leonardi-Bee J, Asselbergs FW, Patel RS, Durrington P, Wierzbicki AS, et al. Predicting major adverse cardiovascular events for secondary prevention: protocol for a systematic review and meta-analysis of risk prediction models. BMJ Open 2020; 10: e034564.
https://doi.org/10.1136/bmjopen-2019-034564 DOI: https://doi.org/10.1136/bmjopen-2019-034564
Breslow NE, Day NE. Statistical methods in cancer research. Volume II: The design and analysis of cohort studies. IARC Sci Publ 1987: 1–406.
Zaaroura H, Gilding AJ, Sibbald C. Biomarkers in alopecia areata: a systematic review and meta-analysis. Autoimmun Rev 2023; 22: 103339.
https://doi.org/10.1016/j.autrev.2023.103339 DOI: https://doi.org/10.1016/j.autrev.2023.103339
Glickman JW, Dubin C, Renert-Yuval Y, Dahabreh D, Kimmel GW, Auyeung K, et al. Cross-sectional study of blood biomarkers of patients with moderate to severe alopecia areata reveals systemic immune and cardiovascular biomarker dysregulation. J Am Acad Dermatol 2021; 84: 370–380.
https://doi.org/10.1016/j.jaad.2020.04.138 DOI: https://doi.org/10.1016/j.jaad.2020.04.138
George P, Jagun O, Liu Q, Wentworth C, Napatalung L, Wolk R, et al. Incidence rates of infections, malignancies, thromboembolism, and cardiovascular events in an alopecia areata cohort from a US Claims Database. Dermatol Ther (Heidelb) 2023; 13: 1733–1746.
https://doi.org/10.1007/s13555-023-00937-9 DOI: https://doi.org/10.1007/s13555-023-00937-9
Chen CC, Chang YT, Liu HN, Chen YJ. Cancer risk in patients with alopecia areata: a nationwide population-based matched cohort study. Cancer Med 2018; 7: 2153–2159.
https://doi.org/10.1002/cam4.1448 DOI: https://doi.org/10.1002/cam4.1448
Miller R, Conic RZ, Bergfeld W, Mesinkovska NA. Prevalence of comorbid conditions and sun-induced skin cancers in patients with alopecia areata. J Investig Dermatol Symp Proc 2015; 17: 61–62.
https://doi.org/10.1038/jidsymp.2015.44 DOI: https://doi.org/10.1038/jidsymp.2015.44
Mostaghimi A, Qureshi S, Joyce C, Guo Y, Huang KP. Reduced incidence of skin cancer in patients with alopecia areata: a retrospective cohort study. Cancer Epidemiol 2016; 41: 129–131.
https://doi.org/10.1016/j.canep.2016.02.009 DOI: https://doi.org/10.1016/j.canep.2016.02.009
Kridin K, Laufer-Britva R, Jimenez F, Cohen AD, Kaplan B, Lyakhovitsky A. Alopecia areata and malignancies: uncertainties clarified by a large-scale population-based study. Arch Dermatol Res 2024; 316: 678.
https://doi.org/10.1007/s00403-024-03385-3 DOI: https://doi.org/10.1007/s00403-024-03385-3
Schneeweiss MC, Kim SC, Wyss R, Jin Y, Chin K, Merola JF, et al. Incidence of venous thromboembolism in patients with dermatologist-diagnosed chronic inflammatory skin diseases. JAMA Dermatol 2021; 157: 805–816.
https://doi.org/10.1001/jamadermatol.2021.1570 DOI: https://doi.org/10.1001/jamadermatol.2021.1570
Huang KP, Joyce CJ, Topaz M, Guo Y, Mostaghimi A. Cardiovascular risk in patients with alopecia areata (AA): a propensity-matched retrospective analysis. J Am Acad Dermatol 2016; 75: 151–154.
https://doi.org/10.1016/j.jaad.2016.02.1234 DOI: https://doi.org/10.1016/j.jaad.2016.02.1234
Sundboll J, Adelborg K, Munch T, Froslev T, Sorensen HT, Botker HE, et al. Positive predictive value of cardiovascular diagnoses in the Danish National Patient Registry: a validation study. BMJ Open 2016; 6: e012832.
https://doi.org/10.1136/bmjopen-2016-012832 DOI: https://doi.org/10.1136/bmjopen-2016-012832
Adelborg K, Sundboll J, Munch T, Froslev T, Sorensen HT, Botker HE, et al. Positive predictive value of cardiac examination, procedure and surgery codes in the Danish National Patient Registry: a population-based validation study. BMJ Open 2016; 6: e012817.
https://doi.org/10.1136/bmjopen-2016-012817 DOI: https://doi.org/10.1136/bmjopen-2016-012817
Jørgensen LK, Dalgaard LS, Østergaard LJ, Andersen NS, Nørgaard M, Mogensen TH. Validity of the coding for herpes simplex encephalitis in the Danish National Patient Registry. Clin Epidemiol 2016; 8: 133–140.
https://doi.org/10.2147/CLEP.S104379 DOI: https://doi.org/10.2147/CLEP.S104379
Egeberg A, Anderson S, Edson-Heredia E, Burge R. Comorbidities of alopecia areata: a population-based cohort study. Clin Exp Dermatol 2021; 46: 651–656.
https://doi.org/10.1111/ced.14507 DOI: https://doi.org/10.1111/ced.14507
Mostaghimi A, Gao W, Ray M, Bartolome L, Wang T, Carley C, et al. Trends in prevalence and incidence of alopecia areata, alopecia totalis, and alopecia universalis among adults and children in a US employer-sponsored insured population. JAMA Dermatol 2023; 159: 411–418.
https://doi.org/10.1001/jamadermatol.2023.0002 DOI: https://doi.org/10.1001/jamadermatol.2023.0002
Additional Files
Published
How to Cite
License
Copyright (c) 2025 Sissel Brandt Toft Sørensen, Prethibha George, Oladayo Jagun, Robert Wolk, Lynne Napatalung, Samuel H. Zwillich, Lars Iversen, Vera Ehrenstein
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
